IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
IGC Pharma is preparing for the Phase 2 topline readout of its lead asset IGC-AD1 in the fourth quarter of 2026, having randomized 160 participants in the CALMA trial to date. The company expects to close enrollment after up to eight additional randomizations and has engaged OPIS Research to assist with EMA regulatory interactions.
Key figures
- Drug Name
- IGC-AD1
- Phase Of Trial
- Phase 2
- Topline readout timing
- Q4 2026
- Participants randomized
- 160
- Additional participants expected
- up to 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.